A high-resolution (1)H NMR study of serum and urine of fulminant hepatic failure patients (n = 22) [surviving (n = 12) and non-surviving (n = 10)] is reported. Glutamine in serum and urine glutamine:creatinine ratio were higher in non-surviving patients compared with surviving patients [serum glutamine, 3.08 (1.68-7.11) vs 0.56 (0.34-0.99) mM, median and range; p = 0.0001 and urine glutamine:creatinine ratio, 1.72 (0.24-7.76) vs 0.39 (0.1-0.84), p = 0.1], and urine urea:creatinine ratio was higher in surviving patients compared with non-surviving patients [10.83 (0.2-22.6) vs 2.09 (0.96-4.0), p = 0.002]. On the other hand, no significant differences were found in the conventionally employed clinical parameters such as serum alanylaminotransferase, aspartylaminotransferase and bilirubin except prothrombin time (p = 0.02). The difference in serum glutamine and urine urea was significant in the two categories of patients and distinctly different values of serum glutamine for both the categories of patients correctly predicted the outcome. These results promise immense potential for NMR spectroscopy in rapidly deciding on the need for advanced therapeutic intervention such as artificial liver support or emergency liver transplantation in FHF.
The Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome Coronavirus-2 (SARS CoV-2) infection attacking mainly on the immune system of a body. It is a potentially fatal disease that is of public health and economy concern globally. In December 2019, COVID-19 outbreak occurred in Wuhan city, Hubei Province, China furthermore spread worldwide. Research is underway in many countries to develop effective vaccines and drugs for the COVID-19. In Ayurveda, Acharya Charaka explained the concept of an epidemic condition in Janapadodhwans Adhayay and combating of these diseases is to be done by Panchakarma (five procedures of purification), Rasayana Chikitsa (immune-modulators therapy) and Sadvritta (good conduct). Rasayan dravyas (immuno modulators drugs) of Ayurveda can be used for health promotion, immune-modulation, prevention and reduce disease burden from COVID-19. Drugs such as Ashwagandha (Withania somnifera (L.) Dunal), Guduchi (Tinospora cordifoloia (Willd.) Miers), Amalaki (Phyllanthus emblica L.), Mulethi (Glycyrrhiza glabra L.), Shatavari (Asparagus racemosus Willd), Chireta (Andrographis paniculata (Burm.f.) Nees), Tulsi (Ocimum sanctum L.) Punarnava (Boerhaavia diffusa L.) and Pippali ((Piper longum L.) For symptom management of COVID-19 like illness Agastya Haritaki, Anutaila, AYUSH–64 can be used. Scientific research on these drugs may reveal the new approach for the prevention and management of COVID-19. The main aim of this article is to review research which has already conducted and currently being carried out on the herbal plant for their immunomodulation property which have a possible application in the prevention and treatment of COVID-19.
Background: Hepatitis B virus (HBV), hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections are prevalent throughout the world. HIV infection increases the risk of HBV and HCV liver disease especially when HIV-associated immunodeficiency progresses. Aims and Objectives: This study was carried out with the objectives as follows: Estimation of the prevalence of HIV- Hepatitis co-infection, determine CD4+T lymphocyte count in co-infected patients, identify most common opportunistic infections in HIV – Hepatitis co- infection. Materials and Methods: A hospital-based, prospective, cross-sectional, and observational study was carried among people with confirmed HIV infection. HIV antibody, hepatitis B surface antigen (HBsAg), and HCV antibody tests were done in all patients visiting to integrated counseling and testing center. HIV, HBV, and HCV viral load were done in all serologically confirmed patients. In HBsAg positive patients various markers for hepatitis such as hepatitis B envelop antigen (HBeAg), anti-hepatitis B core antibody (HBcAb), and anti-hepatitis B envelop antibody were also done. Results: Out of 357 people living with HIV/AIDS (PLHA) patients 15/357 (4.20%) were co-infected with HBV, 03/357 (0.84%) were co-infected with HCV. The overall seroprevalence of Hepatitis virus (HBV+HCV) in PLHA patients was found to be 5.04% (18/357). CD4+T lymphocyte count <200 cells/μL was seen in 66/339 (19.4%), 04/15 (26.6%), and 03/03 (100%) patients of HIV mono-infected, HBV co-infected, and in HCV co-infected patients, respectively. HIV Viral load ≤1000 copies/mL was seen in 324 and 15 patients in HIV mono-infected and HIV- hepatitis co-infected patient, respectively. Among PLHA patients who were positive for HBsAg; 46.7% (n=7) patients had HBV viral load >2000 IU/mL. All hepatitis B co-infected patients were positive for HBcAb test; HBeAg was positive in 40% (n=06). All HBeAg positive were having viral load >2000 IU/mL. Conclusion: HIV-infected patients are more prone to hepatitis associated liver diseases and exposure to the HBV infection than the general population.
In December 2019, an outbreak of severe acute respiratory syndrome Coronavirus (SARSCoV-2) infection occurred in Wuhan city, Hubei Province, China (East Asia) furthermore worldwide including India. On 30 January 2020, the first case of the COVID-19 pandemic was reported in India. India has reached more than 1.5 lakh confirmed cases including more than 4000 fatalities by dreadful COVID-19 infection. At present, there is no vaccine for prevention or medicine for treatment. Only preventive measures like frequently hand-wash by soap and water, or hand sanitizers along with social distancing are effective to avoid the exposure of this virus. Ayurveda is the oldest acknowledged organized medicine on the earth. Immunity has an important role in maintaining health and prevention of diseases. In Ayurveda, Rasayana drugs are known for their immunomodulation and rejuvenation properties. On March 31, 2020, Ministry of AYUSH has issued advisory for enhancing immunity through lifestyle modification, dietary management, prophylactic interventions and simple remedies based on the symptoms. After that successful implementation, Government of India has planned to conduct clinical trials on three herbal nootropic and immunomodulatory drugs viz. Ashwagandha, Guduchi and Mulethi and AYUSH-64 (Ayurvedic anti-malaria drug) for their preventive properties against Covid-19 infections. This review article covers summary of the COVID-19 i.e. transmission, clinical presentation, investigation and prevention along with preventive measures in according to Ayurveda that can be adopted for future clinical trial.
This paper is an implementation of genetic algorithm over SVD-based signal detection in cognitive radio networks in wireless communication system. We simulated the proposed algorithm for detection of common mpsk signal and analyze the performance of detector for blind signal detection where the knowledge of primary user is not present. The paper shows the better results and comparison is between the SVD based signal detection method and proposed method for cognitive radio networks.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.